Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.

CONCLUSIONS: We found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups. PMID: 28984429 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28984429?dopt=Abstract

Source: Medical History - October 6, 2017 Category: History of Medicine Authors: Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A, EuroSIDA Study Tags: HIV Med Source Type: research